

# **Drug Delivery in Cancer**

## **Part I: Technologies & Markets**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
Basel, Switzerland

**April 2018**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 476 publications include 30 books (6 as editor+ 24 as author) and 50 commercial reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Edited books include "Drug Delivery Systems" (1<sup>st</sup> ed Humana/Springer 2008; 2<sup>nd</sup> ed 2014) and "Drug Delivery to the Central Nervous System" (Humana/Springer, 2010). As an author, his recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese edition, Peking University Press 2011; 2<sup>nd</sup> ed Springer 2012, 3<sup>rd</sup> ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical industry Press 2016, 2<sup>nd</sup> ed Springer 2017), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer, 2014). He has edited "Applied Neurogenomics" (Springer 2015).

## **A B O U T   T H I S   R E P O R T**

The original report on Drug Delivery in Cancer by the author was published by Decision Resources Inc in 2000 as an enlargement of the chapter on this topic in his report on Drug Delivery Technologies (1998), which was also published by Decision Resources. The second edition was published at Jain PharmaBiotech in 2003 and has been constantly updated and rewritten since then.

**April 2018 (first edition published in 2000)**  
**Copyright © 2018 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:       +4161-6924461**  
**Email:            info@pharmabiotech.ch**  
**Web site:         http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>19</b>
<b>1. Introduction to cancer therapy .....</b>	<b>21</b>
<b>Molecular biology of cancer .....</b>	<b>21</b>
Cell cycle and cancer .....	21
<i>Apoptosis in cancer</i> .....	22
<i>Autophagy</i> .....	22
<i>Cell division and mitotic spindles</i> .....	23
<i>PD-1 Pathway</i> .....	23
<i>DNA damage, repair and cancer</i> .....	24
<i>Mechanism of DNA damage in Fanconi anemia leading to leukemia</i> .....	24
Cancer metabolism and energy status in relation to growth.....	24
<i>Amino acids and cancer</i> .....	24
<i>AMP-activated protein kinase</i> .....	25
<i>Cancer therapeutics that target metabolism.</i> .....	25
Cancer cell dormancy .....	26
<i>Dormancy and relapse in cancer</i> .....	26
<i>Activating dormant cancer cells for enhancing chemotherapy</i> .....	26
Chromosomes and cancer .....	27
<i>Aneuploidy</i> .....	27
<i>Chromosomal instability</i> .....	27
<i>Telomeres and cancer</i> .....	28
Genes and cancer .....	28
<i>Accumulation of random mutations</i> .....	29
<i>Oncogenes</i> .....	29
<i>Role of Bub 1 gene in cell division</i> .....	29
<i>Tumor Suppressor Genes</i> .....	30
Hallmarks of cancer.....	31
Invasion and metastases .....	31
<i>Tumor suppressor genes and metastases</i> .....	33
Methylation and cancer.....	33
Nitric oxide and cancer .....	33
Inflammation, NO and colon cancer.....	34
Tumor hypoxia and NO .....	35
<i>NO and p53 mutations</i> .....	35
<i>NO and matrix metalloproteinase</i> .....	36
<i>Role of NO in angiogenesis in cancer</i> .....	36
Oxidative stress and cancer.....	37
Role of platelet-derived growth factor in proliferation of cancer.....	38
RNA and cancer .....	38
<i>Anticancer treatments based on RNA regulation of genes</i> .....	38
<i>Role of microRNAs in cancer</i> .....	38
Stem cells and cancer.....	39
Self-sufficiency of tumor proliferation .....	40
Therapeutic implications of apoptosis in cancer.....	40
Tumor angiogenesis .....	42
<i>Pathomechanism of angiogenesis</i> .....	42
<i>Role of VEGF in angiogenesis</i> .....	44
<i>Matrix stiffness-mediated angiogenesis in tumors</i> .....	44
<b>Cancer biomarkers.....</b>	<b>44</b>
Molecular imaging of cancer .....	45
<b>Cancer genomics.....</b>	<b>45</b>
Gene expression profiling in cancer .....	45
<b>Cancer proteomics .....</b>	<b>46</b>
<b>Limitations of genomics and proteomics for understanding cancer .....</b>	<b>46</b>
<b>Cancer microenvironment.....</b>	<b>46</b>
<b>Epidemiology of cancer.....</b>	<b>47</b>
<b>Current management of cancer.....</b>	<b>47</b>
Anticancer drugs.....	48
<i>Limitations of cancer chemotherapy</i> .....	48
Biological therapies for cancer .....	49
Radiotherapy .....	49
<i>Brachytherapy</i> .....	49
Ideal anticancer agent.....	49
Surgery .....	49
<b>Basics of drug delivery in cancer .....</b>	<b>50</b>
Role of mechanical forces in tumor growth and delivery of therapy .....	50
<b>Methods of assessing drug delivery in cancer .....</b>	<b>50</b>

Positron emission tomography (PET) .....	50
<b>Historical landmarks in cancer drug delivery .....</b>	<b>51</b>

<b>2. Innovative treatments for cancer .....</b>	<b>53</b>
<b>Introduction .....</b>	<b>53</b>
<b>Selective estrogen receptor modulators .....</b>	<b>54</b>
<b>Antiangiogenic strategies for cancer .....</b>	<b>55</b>
Development of antiangiogenic therapies .....	55
Classification of antiangiogenic agents .....	56
Examples of antiangiogenic agents .....	57
<i>ACE-041</i> .....	57
<i>Angiopoietin-2 as a target</i> .....	57
<i>Chemotherapy at lower than maximum tolerated dose</i> .....	57
<i>Galectin-3 as a target for inhibiting angiogenesis</i> .....	58
<i>Inhibitors of endothelial proliferation</i> .....	58
<i>Inducers of apoptosis of endothelial cells of tumor vessels</i> .....	58
<i>Lodamin</i> .....	59
<i>Matrix metalloproteinase inhibitors</i> .....	59
<i>Monoclonal antibodies with vasculostatic properties</i> .....	60
<i>PPAR<math>\alpha</math> agonists</i> .....	61
<i>Rapalogues as antiangiogenic agents</i> .....	61
<i>VEGF Trap</i> .....	62
Agents that decrease the permeability of tumor blood vessels .....	62
Antiangiogenic agents in clinical trials .....	62
Antiangiogenic therapy resistance .....	63
Combination of antiangiogenic with cytotoxic therapy .....	63
Antiangiogenic therapy for hematological malignancies .....	63
<b>Bacterial anticancer agents .....</b>	<b>64</b>
Tumor-targeted bacteria .....	65
<i>Bacterial protein for targeted delivery of liposomal cancer drugs</i> .....	65
<i>Bacterial carriers for targeted drug delivery to brain tumors</i> .....	65
<i>Genetically modified bacteria as anticancer agents</i> .....	66
<i>Live bacteria for delivering radioactive anticancer agents</i> .....	67
<i>Synchronized cycles of bacterial lysis with delivery of chemotherapy</i> .....	67
<i>Genetically altered strains of Salmonella as anticancer drug vectors</i> .....	67
Inactivated but metabolically active bacteria .....	68
Bacterial toxins targeted to tumors .....	68
<i>Immunotoxins</i> .....	68
<i>Escherichia Coli toxins</i> .....	69
<i>Engineered anthrax toxin</i> .....	69
<i>Recombinant fusion toxins</i> .....	69
Type III secretion systems .....	71
Induction of apoptosis in cancer by bacterial proteins .....	71
Induction of immune response by bacteriolytic therapy .....	72
<b>Epigenetic targets for anticancer therapy .....</b>	<b>72</b>
<b>Innovations in cell therapy for cancer .....</b>	<b>72</b>
Stem cell transplantation for cancer .....	73
Cancer drug/gene delivery by mesenchymal stem cells .....	73
<b>Cancer immunotherapy .....</b>	<b>74</b>
Cytokines .....	74
Epigenetic modulators and cancer immunotherapies .....	75
STING activation and antitumor immunity .....	77
Cancer vaccines .....	77
<i>5T4 as a target for cancer immunotherapy</i> .....	78
<i>Adoptive cell therapy</i> .....	78
<i>Antigen-specific cancer vaccines</i> .....	81
<i>Carcinoembryonic antigen-based vaccines</i> .....	82
<i>Carbohydrate-based cancer vaccines</i> .....	82
<i>Dendritic cells for cancer vaccination</i> .....	82
<i>Hybrid cell vaccination</i> .....	84
<i>SMART vaccines</i> .....	85
<i>Salmonella-based oral vaccine delivery</i> .....	85
<i>Tumor cell vaccines</i> .....	85
<i>Vaccines that simultaneously target different cancer antigens</i> .....	86
<i>Vaccines based on multiple tumor-associated peptides</i> .....	86
<i>Vaccine for cancer based on antimalaria protein</i> .....	87
Cancer Vaccine Consortium .....	87
Chemoimmunotherapy .....	87
Concluding remarks about cancer vaccines .....	88
Targeted delivery of peptides to tumor-associated macrophages .....	88
Targeting cancer stem cells .....	88

<b>Monoclonal antibodies .....</b>	<b>89</b>
Murine MAbs .....	89
Humanized MAbs .....	89
Actions and uses of MAbs in cancer .....	90
<i>Anti PD-1 and anti PD-L1 MAbs</i> .....	91
Targeted antibody-based cancer therapy .....	91
<i>Antibody-cytokine fusion proteins</i> .....	91
<i>Antibody ARGX-115 for targeting immunosuppressive effect of Tregs</i> .....	91
<i>Antibody J591 for targeted delivery of anticancer therapy</i> .....	91
<i>Anti-Thomsen-Friedenreich antigen MAb</i> .....	92
<i>Combining MAbs with anti-CD55 antibody</i> .....	92
<i>MAbs targeted to alpha fetaprotein receptor</i> .....	92
<i>MAbs that target angiogenesis</i> .....	93
MAbs for immune activation .....	93
Delivery of cancer therapy with MAbs .....	93
Antibody-directed enzyme prodrug therapy .....	94
Chemically programmed antibodies .....	95
Combining diagnostics with therapeutics based on MAbs .....	95
Radiolabeled antibodies for detection and targeted therapy of cancer .....	95
Other innovations for administration of antibodies .....	98
<i>Bispecific antibodies</i> .....	98
<i>Trifunctional antibodies</i> .....	99
<i>Tetravalent bispecific antibodies</i> .....	99
<i>Immunotoxins</i> .....	100
<i>Immunoliposomes</i> .....	100
<i>Combined use of MAbs and cytokines</i> .....	100
<i>huHMFG1-huDNase I</i> .....	101
<i>MAbs that selectively target cancer</i> .....	101
G-MAB technology .....	102
NanoMAbs for targeting cancer .....	102
Advantages and limitations of MAbs for cancer therapy .....	103
Antibody-drug conjugates .....	104
<i>Kadcyla</i> .....	105
<i>Adcetris</i> .....	105
Antibody-enzyme conjugates .....	106
Current and future trends in antibody-based cancer drugs .....	106
<b>Innovative methods of radiation delivery .....</b>	<b>106</b>
Image-guided ultrasound technology for delivery of radiation .....	106
Respiratory gating technology for radiation therapy .....	106
Positron therapy .....	107
Boron neutron capture therapy .....	107
<i>Application of drug delivery systems to BNCP</i> .....	108
<i>Use of nanotechnology to enhance BNCT</i> .....	109
<b>Ion channels and transporters in cancer .....</b>	<b>109</b>
<b>Irreversible electroporation .....</b>	<b>110</b>
<b>Methods to overcome multidrug resistance (MDR) .....</b>	<b>110</b>
Mechanism of MDR .....	110
<i>MDR-associated protein gene</i> .....	111
<i>P-glycoprotein-mediated MDR</i> .....	111
Strategies for overcoming MDR .....	111
<i>Blocking the action of P-glycoprotein</i> .....	111
<i>Combination of targeted drugs with different specificities</i> .....	112
<i>Enzyme Catalyzed Therapeutic Activation</i> .....	112
<i>Inhibition of DNA repair</i> .....	112
<i>Iron chelators that overcomes resistance to chemotherapeutics</i> .....	113
<i>Liposome formulation of anticancer drugs</i> .....	113
<i>Modification of the chemical structure of the anticancer drug</i> .....	114
<i>Managing resistance to antiapoptotic action of anticancer agents</i> .....	114
<i>Modulation of SPARC expression</i> .....	114
<i>Nanoparticles for producing reactive oxygen species in mitochondria</i> .....	114
<i>Nitric oxide inducers</i> .....	115
<i>Proton pump inhibitors</i> .....	115
<i>Repression of Prohibitin1 in drug-resistant cancer cells</i> .....	115
<i>Targeting proteins associated with cancer stem cells</i> .....	115
<b>Targeted cancer therapies .....</b>	<b>116</b>
Targeting cellular pathways .....	116
Targeting antigens in virus-associated cancer .....	117
Targeting the IGF-I receptor .....	117
Targeting Mcl-1 protein .....	117
Targeting mitochondrial membranes .....	117
Targeting tumor lymphatics .....	119

<i>LyP-1 for targeting tumor lymphatics</i> .....	119
Targeting tyrosine kinase receptors.....	119
<i>Inhibitors of bcr-abl tyrosine kinase</i> .....	119
<i>Inhibition of multiple tyrosine kinases</i> .....	120
<i>Inhibitors of ErbB tyrosine kinase</i> .....	120
Targeting the Hedgehog signaling pathway .....	121
Targeting caspase-8 .....	121
Targeting metallodrugs to tumor cells.....	122
Targeting oncogenes .....	122
Targeting miRNA for cancer therapeutics .....	123
Targeting the transferrin receptor-mediated endocytosis pathway .....	123
Targeted anticancer therapies based on the Rad51 promoter.....	123
Targeting cancer stem cells.....	123
Targeting glycolytic pathway in cancer.....	125
Targeting glycoproteins .....	125
<i>Tagging cancer with modified sugars</i> .....	126
<i>Anticancer agents based on glycobiology</i> .....	126
<i>Targeting cell surface glycoproteins</i> .....	126
<i>Biofusion for targeted cancer therapy</i> .....	126
Targeting knottin peptides .....	127
Tarveda's Pentarin platform for targeted drug conjugates .....	127
<b>Enhancing the effects of radiation and chemotherapy .....</b>	<b>128</b>
Sensitizing and enhancing agents for chemotherapy.....	128
<i>CoFactor to enhance the efficacy of chemotherapy</i> .....	128
<i>Enzyme-enhanced chemotherapy</i> .....	128
<i>Resveratrol and quercetin for cardioprotection against chemotherapy</i> .....	129
<i>Tesmilifene for chemosensitization</i> .....	129
Sensitizing agents for radiotherapy .....	129
<i>IPdR</i> .....	129
<i>Ultrasound for enhancing response to radiation</i> .....	130
Manipulation of tumor oxygenation .....	130
<i>Hypoxia-based methods to enhance chemotherapy and radiotherapy</i> .....	130
<i>Hyperbaric oxygen and radiation</i> .....	131
<i>HIF-1 antagonists to enhance radiotherapy</i> .....	131
<i>Nonsteroidal antiinflammatory drugs enhance tumor radiosensitivity</i> .....	132
<i>ONCONASE as radiosensitivity enhancer</i> .....	132
Hyperthermia and chemotherapy/radiation therapy.....	132
<i>Techniques for hyperthermia</i> .....	132
<i>Trimodality therapy: radiation, chemotherapy, and hyperthermia</i> .....	133
Photodynamic therapy .....	133
<i>Photochemical internalization</i> .....	136
Thermal combination with focused ultrasound for drug delivery to tumors.....	136
<b>Novel anticancer agents .....</b>	<b>136</b>
Anti-EphA2 antibodies .....	136
Antioxidants.....	137
Bristollicin .....	137
Agents disrupting folate metabolism.....	137
<i>Pemetrexed</i> .....	137
Cell cycle inhibitors .....	138
Cytotoxic ribonucleases .....	138
DNA hypomethylating agents .....	139
Histone-based cancer therapy .....	139
<i>Histone deacetylase inhibitors</i> .....	139
<i>Modulation of p300/CBP histone acetyltransferase activity</i> .....	140
<i>Simulation of endogenous histone for anticancer therapy</i> .....	140
HSP90 inhibitors .....	141
Ion channel blockers .....	141
<i>IOT-101</i> .....	141
<i>Endovion</i> .....	142
LPAAT- $\beta$ inhibitors.....	142
Modulation of pyruvate kinase M2 .....	142
Modulators of protein ubiquitination .....	142
P13-kinase inhibitors.....	143
PARP inhibitors .....	143
<i>Targeted destruction of BRCA2 deficient tumors by PARP inhibitors</i> .....	143
<i>Companies developing and commercializing PARP inhibitors</i> .....	144
Prodrugs.....	145
<i>Enzyme-activated prodrugs</i> .....	145
<i>Ascorbic acid as a prodrug for cancer</i> .....	145
<i>Prolarix</i> .....	145
Procaspase-3 activation .....	145

Protein kinase G activation.....	146
Proteasome inhibitors.....	146
Recombinant human insulin-like growth factor binding protein-3.....	146
Second generation nucleosides.....	147
Targeting cancer metabolism.....	147
Targeting topoisomerase IB.....	148
Telomerase inhibitors.....	149
Therapeutic strategies based on the P53 pathway.....	149
Therapeutic strategies based on molecular mechanisms.....	150
<i>Checkpoint activation as a strategy against cancer</i> .....	150
<i>Deletion-specific targeting for cancer therapy</i> .....	150
<i>In vivo models for molecularly anticancer drugs</i> .....	151
<i>Repair-blocking drugs for enhancing effect of chemotherapy</i> .....	151
<i>Tumor targeting fields</i> .....	151
<i>Targeting mTOR signaling defects</i> .....	152
Combining novel anticancer approaches.....	152
<b>Personalized therapy of cancer.....</b>	<b>153</b>
Challenges of cancer classification.....	155
Design of future cancer therapies.....	156
Personalized drug development in oncology.....	156
<i>Role of molecular imaging</i> .....	156
<i>Role of molecular imaging in targeted cancer therapy</i> .....	157
<i>Screening for personalized anticancer drugs</i> .....	158
<i>Targeting pathways for personalized cancer therapy</i> .....	158
<b>3. Drug delivery systems for cancer.....</b>	<b>159</b>
<b>Introduction.....</b>	<b>159</b>
<b>Routes of drug delivery in cancer.....</b>	<b>159</b>
Intravenous delivery systems for cancer therapy.....	160
<i>Intravenous versus oral ascorbate for treatment of cancer</i> .....	161
Subcutaneous injection of anticancer agents.....	161
Oral delivery of anticancer agents.....	161
<i>5-FU combined with eniluracil</i> .....	163
<i>Cyclin D-dependent CDK4 and CDK6 inhibitors</i> .....	163
<i>High dose administration of calcitriol</i> .....	163
<i>Oral fluoropyrimidines</i> .....	164
<i>Oral gefitinib vs intravenous docetaxel</i> .....	164
<i>Oral paclitaxel</i> .....	165
<i>Oral satraplatin</i> .....	165
<i>Oral UFT</i> .....	165
<i>Oral PXD101</i> .....	166
Transdermal drug delivery.....	166
<i>Delivery of the photosensitizer drug <math>\delta</math>-amino levulinic acid</i> .....	166
<i>Nanoemulsion-based delivery of caffeine for skin cancer</i> .....	166
<i>Transdermal delivery of methotrexate</i> .....	167
<i>Transdermal nitroglycerine for prostate cancer</i> .....	167
<i>Transdermal delivery of peptide cancer vaccines</i> .....	167
<i>Intradermal delivery of cancer vaccines by adenoviral vectors</i> .....	167
Pulmonary delivery of anticancer agents.....	168
Regional intra-arterial delivery of chemotherapy.....	168
Gas embolotherapy of tumors.....	169
Drug delivery to lymph nodes.....	169
Intraperitoneal macrophages as drug delivery vehicle.....	170
Challenges of cancer drug delivery.....	170
Tumor blood vessel pore barrier to drug delivery.....	170
Improvement of drug transport in tumors.....	170
Delivery of anticancer drugs to nuclear targets.....	171
<b>Innovative formulations for drug delivery in cancer.....</b>	<b>172</b>
Cancer targeting with polymeric drugs.....	172
<i>Linking anticancer drugs to polyglutamate</i> .....	173
<i>Improving delivery of protein-polymer anticancer drugs</i> .....	173
Macromolecules as delivery systems for taxanes.....	174
Polyamine conjugates as anticancer agents.....	174
Bacterial vectors as drug delivery systems for anticancer drugs.....	174
Microparticles as therapeutic delivery systems in cancer.....	175
<i>Subcutaneous injection of microspheres carrying anticancer drugs</i> .....	175
<i>Intravascular delivery systems using microparticles</i> .....	176
<i>Tumor embolization with drug-eluting beads</i> .....	176
<i>Tumor embolization with radioactive microparticles</i> .....	176
<i>Microparticles heated by magnetic field</i> .....	177
<i>Magnetic targeted microparticle technology</i> .....	177

Release of drugs from biSphere by ultrasound .....	177
Release of drugs from micelles by ultrasound .....	178
Release of drugs from microcapsules by laser .....	178
Chemoembolization .....	179
Anticancer drugs bound to carbon particles .....	179
Anticancer drugs bound to protein microspheres .....	179
Nanoerythroosomes .....	179
Micronized droplets of olive oil .....	179
<b>Nanobiotechnology-based drug delivery for cancer .....</b>	<b>180</b>
Nanoparticle formulations for drug delivery in cancer .....	181
Anticancer drug particles incorporated in liposomes .....	181
Doxorubicin nanocarriers .....	183
Encapsulating drugs in hydrogel nanoparticles .....	184
Exosomes .....	184
Folate-linked nanoparticles .....	185
Lipid based nanocarriers .....	185
Micelles for drug delivery in cancer .....	185
Minicells for targeted delivery of nanoscale anticancer therapeutics .....	187
Nanobombs for cancer .....	187
Nanodiamonds for local delivery of chemotherapy at site of cancer .....	188
Nanoparticle formulation for enhancing anticancer efficacy of cisplatin .....	188
Nanoparticle formulations of paclitaxel .....	189
Nanoparticles containing albumin and antisense oligonucleotides .....	189
Nanotechnology-based non-invasive refilling of drug delivery depots .....	189
Non-aggregating nanoparticles .....	190
Pegylated nanoliposomal formulation .....	190
Perfluorocarbon nanoparticles .....	190
Polymer nanoparticles for drug delivery .....	190
Protein nanocages for penetration of airway mucous and tumors .....	191
Protosphere nanoparticle technology .....	191
Nanoparticles-based targeted delivery of therapeutics for cancer .....	192
Antiangiogenic therapy using nanoparticles .....	193
Carbon magnetic nanoparticles for targeted drug delivery in cancer .....	193
Carbon nanotubes for targeted drug delivery to cancer cells .....	194
CRLX101 for targeted anticancer drug delivery .....	194
DNA aptamer-micelle for targeted drug delivery in cancer .....	194
Fullerenes for enhancing tumor targeting by antibodies .....	195
Gold nanoparticles for targeted drug delivery in cancer .....	195
Hepatic artery infusion of LDL-DHA nanoparticles for liver cancer .....	196
Iron oxide magnetic nanoparticle formulation for drug delivery .....	197
Laser irradiation for targeted release of drugs from nanocontainers .....	197
Lipoprotein nanoparticles targeted to cancer-associated receptors .....	197
Magnetic nanoparticles for remote-controlled drug delivery to tumors .....	197
Monitoring of targeted delivery by nanoparticle-peptide conjugates .....	198
Nanobees for targeted delivery of cytolytic peptide melittin .....	198
Nanocell for targeted drug delivery to tumor .....	199
Nanodroplets for site-specific cancer treatment .....	200
Nanogel-based stealth cancer vaccine targeting macrophages .....	200
Nanoparticle-mediated targeted delivery of peptides into tumors .....	200
Nanoparticle-mediated targeting of MAPK signaling pathway .....	201
Nanoparticles for targeted delivery of concurrent chemoradiation .....	201
Nanostructured hyaluronic acid for targeted drug delivery in cancer .....	202
Nanoparticles as antibody-drug conjugates .....	202
Nanoparticle-coated peptides for tumor targeting .....	202
Nanoparticle-mediated delivery of multiple anticancer agents .....	202
Polymer nanoparticles for targeted drug delivery in cancer .....	203
Polymersomes for targeted cancer drug delivery .....	203
Targeted drug delivery with nanoparticle-aptamer bioconjugates .....	204
Targeted nanoparticles delivery of cisplatin to mitochondrial genome .....	204
Time-delayed, dual-drug nanoparticle delivery system for cancer .....	205
Dendrimers for anticancer drug delivery .....	205
Application of dendrimers in boron neutron capture therapy .....	206
Application of dendrimers in photodynamic therapy .....	207
Dendrimer-based synthetic vector for targeted cancer gene therapy .....	207
Devices for nanotechnology-based cancer therapy .....	207
Convection-enhanced delivery with nanoliposomal CPT-11 .....	207
Nanocomposite devices .....	208
Nanoengineered silicon for brachytherapy .....	208
Nanosensors for targeted drug delivery in cancer .....	209
Nanoparticles combined with physical agents for tumor ablation .....	209
Carbon nanotubes for laser-induced cancer destruction .....	209



<i>Nanoparticles and thermal ablation</i> .....	209
<i>Nanoparticles combined with ultrasound radiation of tumors</i> .....	212
<i>Nanoparticles as adjuncts to photodynamic therapy of cancer</i> .....	212
<i>Nanoparticles for boron neutron capture therapy</i> .....	213
RNA nanotechnology for delivery of cancer therapeutics .....	213
Nanocarriers for simultaneous delivery of multiple anticancer agents.....	213
Combination delivery systems for nanoparticle penetration into tumor tissue .....	214
Combination of diagnostics and therapeutics for cancer .....	214
<i>Biomimetic nanoparticles targeted to tumors</i> .....	214
<i>Dendrimer nanoparticles for targeting and imaging tumors</i> .....	214
<i>Gold nanoparticle plus bombesin for imaging and therapy of cancer</i> .....	215
<i>Gold nanorods for diagnosis plus photothermal therapy of cancer</i> .....	215
<i>Magnetic nanoparticles for imaging as well as therapy of cancer</i> .....	216
<i>Nanobialys for combining MRI with delivery of anticancer agents</i> .....	216
<i>Nanorobotics for detection and targeted therapy of cancer</i> .....	216
<i>pHLIP nanotechnology for detection and targeted therapy of cancer</i> .....	217
<i>Polymer nanobubbles for targeted and controlled drug delivery</i> .....	217
<i>Radiolabeled carbon nanotubes for tumor imaging and targeting</i> .....	218
<i>Targeted therapy with magnetic nanomaterials guided by antibodies</i> .....	218
<i>Ultrasonic tumor imaging and targeted chemotherapy by nanobubbles</i> .....	218
<i>Future of nanobiotechnology and targeted cancer therapy</i> .....	219
<b>Polyethylene glycol technology</b> .....	<b>219</b>
Enzon's PEG technology .....	219
Debiopharm's PEG biconjugate drug delivery platform .....	220
Nektar PEGylation .....	220
PEG Intron .....	220
<b>Single-chain antibody-binding protein technology</b> .....	<b>221</b>
<b>Vesicular systems for drug delivery in cancer</b> .....	<b>221</b>
<b>Liposomes for anticancer drug delivery</b> .....	<b>222</b>
Antibody-targeted liposomes for cancer therapy .....	222
ALZA's Stealth liposomes .....	223
Boron-containing liposomes .....	223
DepoFoam technology .....	223
Hyperthermia and liposomal drug delivery .....	224
Liposomal doxorubicin formulation with N-octanoyl-glucosylceramide .....	224
Liposome-nucleic acid complexes for anticancer drug delivery .....	224
Non-pegilated liposomal doxorubicin .....	225
Tumor-selective targeted drug delivery via folate-PEG liposomes .....	225
Ultrasound-mediated anticancer drug release from liposomes.....	225
Companies developing liposome-based anticancer drugs.....	225
<b>Pharmacosomes for controlled anticancer drug delivery</b> .....	<b>226</b>
<b>Emulsion formulations of anticancer drugs</b> .....	<b>227</b>
<b>Albumin-based drug carriers</b> .....	<b>227</b>
<b>Anticancer drugs that bind to tumors</b> .....	<b>228</b>
<b>Monoclonal T cell receptor technology</b> .....	<b>228</b>
<b>Radioactive materials for diagnosis and targeted therapy of cancer</b> .....	<b>228</b>
Peptide receptor radionuclide therapy.....	229
Pretargeted radioimmunotherapy of cancer .....	229
Radiolabeled somatostatin receptor antagonists.....	229
Theophylline enhances radioiodide uptake by cancer .....	229
<b>Strategies for drug delivery in cancer</b> .....	<b>230</b>
Direct introduction of anticancer drugs into the tumor .....	231
<i>Injection into the tumor</i> .....	231
<i>Antineoplastic drug implants into tumors</i> .....	232
<i>Tumor necrosis therapy</i> .....	232
<i>Injection into the arterial blood supply of cancer</i> .....	233
<i>Electrochemotherapy</i> .....	234
<i>Pressure-induced filtration of drugs across vessels to the tumor</i> .....	234
Improving drug transport to tumors .....	235
<i>Carbohydrate-enhanced chemotherapy</i> .....	235
<i>Dextrans as macromolecular anticancer drug carriers</i> .....	235
<i>In situ production of anticancer agents in tumors</i> .....	236
<i>Iotophoresis for localized delivery of cancer chemotherapy</i> .....	236
Strategies for increasing drug penetration into solid cancers .....	236
Selective destruction of cancer cells .....	236
<i>Hyperbaric oxygen</i> .....	237
<i>Sphingolipids</i> .....	237
<i>Targeting response to transformation-induced oxidative stress</i> .....	237
<i>Targeting enzymes to prevent proliferation of cancer cells</i> .....	238
Targeted drug delivery in cancer.....	238
<i>Affibody molecules for targeted anticancer therapy</i> .....	239

<i>Fatty acids as targeting vectors</i> .....	239
<i>Genetic targeting of the kinase activity in cancer cells</i> .....	240
<i>Heat-activated targeted drug delivery</i> .....	240
<i>Novel transporters to target photosensitizers to cancer cell nuclei</i> .....	240
<i>Photodynamic therapy of cancer</i> .....	241
<i>Radionuclides delivered with receptor targeting technology</i> .....	241
<i>Targeting ligands specific for cancer cells</i> .....	242
<i>Targeting abnormal DNA in cancer cells</i> .....	242
<i>Targeted delivery by tumor-activated prodrug therapy</i> .....	242
<i>Targeting glutathione S-transferase</i> .....	244
<i>Targeting tumors by exploiting leaky blood vessels</i> .....	244
<i>Targeted drug delivery of anticancer agents with controlled activation</i> .....	245
<i>Targeted delivery of anticancer agents with ReCODE™ technology</i> .....	245
<i>Transmembrane Carrier Systems</i> .....	245
<i>Transferrin-oligomers as targeting carriers in anticancer drug delivery</i> .....	246
<i>Tumor targeting with peptides</i> .....	246
<i>Ultrasound and microbubbles for targeted anticancer drug delivery</i> .....	246
<i>Ultrasound for targeted delivery of chemotherapeutics</i> .....	247
<i>Vitamin B12 and folate for targeting cancer chemotherapy</i> .....	248
Cell-based drug delivery in cancer.....	249
<i>Red blood cells as vehicles for drug delivery</i> .....	249
<i>Cells as vehicles for gene delivery</i> .....	250
Drug delivery in relation to circadian rhythms.....	250
Implants for systemic delivery of anticancer drugs .....	251
<i>Drug-eluting polymer implants</i> .....	251
Angiogenesis and drug delivery to tumors .....	252
Antiangiogenesis strategies .....	252
<i>Targeting tumor endothelial cells</i> .....	253
<i>Methods for overcoming limitations of antiangiogenesis approaches</i> .....	253
Vascular targeting agents .....	254
<i>Alpha-emitting antibodies for vascular targeting</i> .....	254
<i>Angiolytic therapy</i> .....	255
<i>Anti-phosphatidylserine antibodies as VTA</i> .....	255
<i>Vadimezan</i> .....	255
<i>Cadherin inhibitors</i> .....	256
<i>Fosbretabulin tromethamine</i> .....	256
<i>Drugs to induce clotting in tumor vessels</i> .....	256
<i>Selective permeation of the anticancer agent into the tumor</i> .....	257
<i>Targeted delivery of tissue factor</i> .....	257
<i>Vascular targeting agents versus antiangiogenesis agents</i> .....	258
<i>ZD6126</i> .....	258
Delivery of proteins and peptides for cancer therapy .....	259
<i>CELLECTRA™ electroporation device</i> .....	259
<i>Emisphere's Eligen™ system</i> .....	260
<i>Diatos Peptide Vector intra-cellular/intra-nuclear delivery technology</i> .....	260
<i>Lytic peptides and cancer</i> .....	261
<i>Modification of proteins and peptides with polymers</i> .....	261
<i>Peptide-based targeting of cancer biomarkers for drug delivery</i> .....	261
<i>Peptide-cytokine complexes as vascular targeting agents</i> .....	262
<i>Peptide-polymer conjugates with radionuclides</i> .....	262
<i>Transduction of proteins in vivo</i> .....	262
<i>Tumor targeting by stable toxin (ST) peptides</i> .....	263
Image-guided personalized drug delivery in cancer .....	263
A computational approach to integration of drug delivery methods for cancer.....	263

#### **4. Delivery of Biological Therapies for Cancer..... 265**

<b>Introduction</b> .....	<b>265</b>
<b>Antisense therapy</b> .....	<b>265</b>
Basics of antisense approaches.....	265
Antisense cancer therapy .....	265
Mechanisms of anticancer effect of antisense oligonucleotides .....	266
Selected antisense drugs in development for cancer.....	266
<i>Antisense targeted to ribonucleotide reductase</i> .....	266
<i>Immune modulatory oligonucleotide</i> .....	267
Ribozyme therapy .....	267
Spiegelmers .....	268
Antisense drug delivery issues.....	268
Strategies to overcome delivery problems of antisense oligonucleotides.....	269
<i>Antisense delivery in microspheres</i> .....	269
<i>Delivery of antisense using nanoparticles</i> .....	269
<i>Delivery across the blood-brain barrier</i> .....	270

<i>Delivery of ribozymes</i> .....	270
<i>Iontophoretic delivery of oligonucleotides</i> .....	270
<i>Liposomes-mediated oligonucleotide delivery</i> .....	271
<i>Neugene™ antisense drugs</i> .....	271
<i>Oral delivery of oligonucleotides</i> .....	272
<i>Peptide nucleic acid delivery</i> .....	272
<i>Receptor-mediated endocytosis</i> .....	272
<i>Delivery of ribozymes</i> .....	273
Combination of antisense and electrochemotherapy.....	273
Aptamers for combined diagnosis and therapeutics of cancer.....	273
Antisense compounds in clinical trials.....	274
<b>RNA interference</b> .....	<b>274</b>
Basics of RNAi.....	274
Comparison of antisense and RNAi.....	275
RNAi applications in oncology.....	275
siRNA-based cancer immunotherapy.....	276
Delivery of siRNA in cancer.....	277
<i>Delivery of siRNA by nanoparticles</i> .....	277
<i>Delivery of siRNA by nanosize liposomes</i> .....	278
<i>Lipid nanoparticles for delivery of anticancer siRNAs</i> .....	279
<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i> .....	279
Lipophilic siRNA for targeted delivery to solid tumors.....	280
Companies developing cancer therapies based on antisense and RNAi.....	280
<b>DNA interference</b> .....	<b>281</b>
<b>Cancer gene therapy</b> .....	<b>281</b>
Basics of gene therapy.....	281
Strategies for cancer gene therapy.....	282
Gene transfer techniques as applied to cancer gene therapy.....	283
<i>Viral vectors</i> .....	283
<i>Nonviral vectors</i> .....	284
<i>A polymer approach to gene therapy for cancer</i> .....	284
Direct gene delivery to the tumor.....	285
<i>Injection into tumor</i> .....	285
<i>Reversible electroporation</i> .....	286
Hematopoietic gene transfer.....	287
<i>Genetic modification of human hematopoietic stem cells</i> .....	287
Gene-based strategies for immunotherapy of cancer (immunogene therapy).....	288
<i>Cytokine gene therapy</i> .....	288
Monoclonal antibody gene transfer.....	291
Transfer and expression of intracellular adhesion-1 molecules.....	292
Other gene therapy techniques for immunotherapy of cancer.....	292
<i>Chemokines</i> .....	292
<i>Engineered viruses as anticancer immunotherapy vectors</i> .....	293
<i>Fas (Apo-1)</i> .....	293
<i>IGF (Insulin-Like Growth Factor)</i> .....	293
<i>Major Histocompatibility Complex (MHC) Class I</i> .....	293
Inhibition of immunosuppressive function.....	293
microRNA gene therapy.....	294
Delivery of toxic genes to tumor cells for eradication (molecular chemotherapy).....	294
<i>Gene-directed enzyme prodrug therapy</i> .....	294
Combination of gene therapy with radiotherapy.....	295
Multipronged therapy of cancer with microencapsulated cells.....	296
Correction of genetic defects in cancer cells (mutation compensation).....	296
Targeted gene therapy for cancer.....	297
<i>Transcriptional targeting for cancer gene therapy</i> .....	297
<i>Targeted epidermal growth factor-mediated DNA delivery</i> .....	297
<i>Gene-based targeted drug delivery to tumors</i> .....	297
<i>Targeting gene expression to hypoxic tumor cells</i> .....	298
<i>Targeting gene expression by progression-elevated gene-3 promoter</i> .....	298
<i>Targeted delivery of retroviral particles hitchhiking on T cells</i> .....	299
<i>Targeting tumors with genetically modified T cells</i> .....	299
<i>Targeting tumors by genetically engineered stem cells</i> .....	299
<i>Tumor-targeted gene therapy by receptor-mediated endocytosis</i> .....	300
<i>Targeted site-specific delivery of anticancer genes by nanoparticles</i> .....	300
<i>Immunolipoplex for delivery of p53 gene</i> .....	301
<i>Combination of electrogene and electrochemotherapy</i> .....	301
Virus-mediated oncolysis.....	301
<i>Targeted cancer treatments based on oncolytic viruses</i> .....	301
<i>Oncolytic gene therapy</i> .....	302
<i>Cancer terminator virus</i> .....	302
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i> .....	303

<i>Facilitating oncolysis by targeting innate antiviral response by HDIs</i> .....	303
<i>Oncolytic HSV</i> .....	304
<i>Oncolytic adenoviruses</i> .....	304
<i>Oncolytic Coxsackie virus A21</i> .....	306
<i>Oncolytic vesicular stomatitis virus</i> .....	306
<i>Oncolytic measles virus</i> .....	307
<i>Oncolytic paramyxovirus</i> .....	307
<i>Oncolytic reovirus</i> .....	307
<i>Oncolytic vaccinia virus</i> .....	308
<i>Synthetic oncolytic virus</i> .....	308
<i>Monitoring of viral-mediated oncolysis by PET</i> .....	308
<i>Companies developing oncolytic viruses</i> .....	309
Antiangiogenic therapy for cancer.....	309
Apoptotic approach to improve cancer gene therapy.....	310
Bacteria as novel anticancer gene vectors.....	311
Concluding remarks on cancer gene therapy.....	311
Cancer gene therapy companies.....	312
<b>Cell therapy for cancer</b> .....	<b>314</b>
Cellular immunotherapy for cancer.....	315
Treatments for cancer by ex vivo mobilization of immune cells.....	315
Granulocytes as anticancer agents.....	316
Neutrophil granulocytes in antibody-based immunotherapy of cancer.....	316
Use of hematopoietic stem cells for targeted cancer therapy.....	316
<b>Cancer vaccines</b> .....	<b>317</b>
Cell-based cancer vaccines.....	317
<i>Autologous tumor cell vaccines</i> .....	317
<i>Vaccines that simultaneously target different cancer antigens</i> .....	318
<i>Delivery systems for cell-based cancer vaccines</i> .....	318
<i>Intra-lymph node injections of cancer vaccine antigens</i> .....	319
Nucleic acid-based cancer vaccines.....	319
<i>Antiangiogenic DNA cancer vaccine</i> .....	319
<i>DNA cancer vaccines</i> .....	320
<i>Methods of delivery of DNA vaccines</i> .....	320
<i>RNA vaccines</i> .....	321
Viral vector-based cancer vaccines.....	321
Companies involved in nucleic acid-based vaccines.....	322
Genetically modified cancer cells vaccines.....	323
<i>GVAX cancer vaccines</i> .....	323
<i>Genetically modified dendritic cells</i> .....	324
Mulleptide-based cancer vaccines.....	324
<b>5. Delivery strategies according to cancer type and location</b> .....	<b>325</b>
<b>Introduction</b> .....	<b>325</b>
<b>Bladder cancer</b> .....	<b>325</b>
Intravesical drug delivery.....	325
Intravesical agents combined with systemic chemotherapy.....	325
Targeted anticancer therapy for bladder cancer.....	326
Prodrug EOquin for bladder cancer.....	326
Antisense treatment of bladder cancer.....	327
Gene therapy for bladder cancer.....	327
<b>Brain tumors</b> .....	<b>327</b>
Methods for evaluation of anticancer drug penetration into brain tumor.....	328
Innovative methods of drug delivery for glioblastoma multiforme.....	328
Delivery of anticancer drugs across the blood-brain barrier.....	329
<i>Anticancer agents with increased penetration of BBB</i> .....	329
<i>BBB disruption</i> .....	330
<i>Nanoparticle-based targeted delivery of chemotherapy across the BBB</i> .....	330
<i>Tyrosine kinase inhibitor increases topotecan penetration into CNS</i> .....	332
Bypassing the BBB by alternative methods of drug delivery.....	332
<i>Intranasal perillyl alcohol</i> .....	332
<i>Intraarterial chemotherapy</i> .....	333
Enhancing tumor permeability to chemotherapy.....	333
Local delivery of chemotherapeutic agents into the tumor.....	334
<i>Carmustine biodegradable polymer implants</i> .....	334
<i>Fibrin glue implants containing anticancer drugs</i> .....	335
<i>Biodegradable microspheres containing 5-FU</i> .....	335
<i>Magnetically controlled microspheres</i> .....	335
Convection-enhanced delivery.....	335
<i>CED for receptor-directed cytotoxin therapy</i> .....	335
<i>CED of topotecan</i> .....	336
<i>CED of a modified diphtheria toxin conjugated to transferrin</i> .....	336

<i>CED of nanoliposomal CPT-11</i> .....	337
<i>CED for delivery <sup>131</sup>I-<i>chTNT-1/B MAb</i></i> .....	337
Anticancer drug formulations for targeted delivery to brain tumors .....	337
<i>Intravenous delivery of anticancer agents bearing transferrin</i> .....	337
<i>Liposomes for drug delivery to brain tumors</i> .....	337
<i>MABs targeted to brain tumors</i> .....	338
<i>Multiple targeted drugs for brain tumors</i> .....	338
<i>Nanoparticles for targeted drug delivery in glioblastoma multiforme</i> .....	339
<i>Targeted antiangiogenic/apoptotic/cytotoxic therapies</i> .....	340
<i>Targeted drug delivery to gliomas using cholera toxin subunit B</i> .....	341
Introduction of the chemotherapeutic agent into the CSF pathways.....	341
<i>Intraventricular chemotherapy for meningeal cancer</i> .....	341
<i>Intrathecal chemotherapy</i> .....	342
Interstitial delivery of dexamethasone for reduction of peritumor edema .....	342
Combination of chemotherapy with radiotherapy .....	342
Photodynamic therapy for chemosensitization of brain tumors .....	343
<i>Nanoparticles for photodynamic therapy of brain tumors</i> .....	343
Innovative delivery of radiotherapy to brain tumors .....	344
<i>GliaSite Radiation Therapy System</i> .....	344
<i>Boron neutron capture therapy for brain tumors</i> .....	344
Cell therapy for glioblastoma multiforme.....	344
<i>Chimeric antigen receptor T cells</i> .....	344
<i>Mesenchymal stem cells to deliver treatment for gliomas</i> .....	345
<i>Stem cell-based therapy targeting EGFR in GBM</i> .....	345
Gene therapy for glioblastoma multiforme.....	345
<i>Antiangiogenic gene therapy</i> .....	346
<i>Anticancer drug delivery by genetically engineered MSCs</i> .....	347
<i>Gene transfer to brain tumor across the BBB by nanobiotechnology</i> .....	347
<i>Intravenous gene delivery with nanoparticles into brain tumors</i> .....	347
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i> .....	348
<i>Neural stem cells for drug/gene delivery to brain tumors</i> .....	348
<i>Peptides targeted to glial tumor cells</i> .....	349
<i>RNAi gene therapy of brain cancer</i> .....	349
<i>Single-chain antibody-targeted adenoviral vectors</i> .....	350
<i>Targeting normal brain cells with an AAV vector encoding interferon-<math>\beta</math></i> .....	350
<i>Treatment of medulloblastoma by suppressing genes in Shh pathway</i> .....	350
<i>Virus-mediated oncolytic therapy of glioblastoma multiforme</i> .....	351
Vaccination for glioblastoma multiforme.....	353
<i>Cell-based vaccines for GBM</i> .....	353
<i>Peptide vaccines for GBM</i> .....	353
Oncolytic viral delivery by stem cells for brain metastases of melanoma .....	354
<b>Breast Cancer .....</b>	<b>354</b>
Therapies for breast cancer involving innovative methods of drug delivery .....	355
Injectable biodegradable polymer delivery system for local chemotherapy .....	355
MammoSite brachytherapy.....	356
Monoclonal antibodies targeted to HER2 receptor.....	356
Breast cancer vaccines .....	357
<i>HER-2 DNA AutoVac<sup>TM</sup> vaccine</i> .....	357
<i>Recombinant adenoviral ErbB-2/neu vaccine</i> .....	358
<i>Gene vaccine for breast cancer</i> .....	358
<i>NeuVax</i> .....	359
Gene therapy for breast cancer.....	359
Antisense therapy for breast cancer .....	360
Inhibitors of growth factors FGF2 and VEGF for breast cancer .....	360
Targeted multi-drug delivery approach to breast cancer.....	360
<b>Cancer of the cervix and the uterus .....</b>	<b>361</b>
Gene therapy for cervical cancer.....	361
Delivery of chemoradiation therapy .....	361
Cervical cancer vaccines .....	361
<b>Cancer of the liver .....</b>	<b>362</b>
Hepatocellular carcinoma .....	362
Treatment of liver metastases .....	363
<b>Gastrointestinal cancer.....</b>	<b>363</b>
Colorectal cancer .....	363
<i>Oxaliplatin long-circulating liposomes</i> .....	364
<i>Perifosine</i> .....	364
<i>Targeted delivery of triple anticancer therapy by local patch</i> .....	364
Gastrointestinal stromal tumor .....	364
Vaccines for gastrointestinal cancer.....	365
<b>Hematological malignancies .....</b>	<b>365</b>
Leukemia.....	365

<i>Clofarabine</i> .....	366
<i>Ibrutinib</i> .....	366
<i>Idelalisib for CLL</i> .....	366
Multiple myeloma.....	367
<i>Monoclonal antibody therapy in multiple myeloma</i> .....	367
Non-Hodgkin's lymphoma .....	367
<i>Idelalisib for NHL</i> .....	368
<i>Pixantrone</i> .....	368
<i>Rituximab after autologous stem-cell transplantation</i> .....	368
<b>Malignant melanoma</b> .....	<b>368</b>
Targeted therapies for melanoma .....	369
Immunotherapy for malignant melanoma .....	369
Gene therapy for malignant melanoma .....	370
<b>Nasopharyngeal carcinoma</b> .....	<b>372</b>
Synergistic effect of gene therapy with 5-FU .....	372
<b>Neuroblastoma</b> .....	<b>372</b>
Genetically modified NSCs for treatment of neuroblastoma .....	373
<b>Non-small cell lung cancer</b> .....	<b>373</b>
Aerosol delivery of anticancer agents for lung cancer.....	374
Aerosol gene delivery for lung cancer .....	375
Complex nanoscale pulmonary delivery of drugs for resistant lung cancer .....	375
Intratumoral administration of anticancer drugs through a bronchoscope.....	375
<b>Ovarian cancer</b> .....	<b>376</b>
Dendritic cell vaccination for ovarian cancer .....	376
Gene Therapy for ovarian cancer .....	376
Innovative drug delivery for ovarian cancer.....	377
Intravenous ascorbate for ovarian cancer.....	377
Intraperitoneal delivery .....	378
Intraperitoneal hyperthermic chemotherapy in ovarian cancer .....	378
Modulation of protein ubiquitination .....	379
Targeting Notch pathway to overcome resistance to chemotherapy .....	379
<b>Pancreatic cancer</b> .....	<b>379</b>
Delivery of chemotherapy for pancreatic cancer.....	380
<i>Local drug delivery</i> .....	380
<i>Localized drug delivery by iontophoresis</i> .....	380
<i>Nanoparticle-based delivery of tumor-penetrating peptides</i> .....	380
<i>Targeted chemotherapy for pancreatic cancer</i> .....	381
<i>Transport properties of pancreatic cancer and gemcitabine delivery</i> .....	381
Vaccine for pancreatic cancer .....	382
Gene therapy for pancreatic cancer.....	382
<i>Correction of altered genes</i> .....	382
<i>Targeted gene therapy</i> .....	382
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens</i> .....	383
<i>Targeted Expression of BikDD gene</i> .....	383
<i>Viral oncolysis in pancreatic cancer</i> .....	383
<b>Prostate cancer</b> .....	<b>383</b>
Alpha emitter radium-223 for targeting bone metastases in cancer .....	384
Brachytherapy for cancer of prostate.....	385
<i>Brachytherapy via paravertebral approach lymph node metastases</i> .....	385
Capridine-beta.....	385
LHRH for prostate cancer .....	386
<i>LHRH analogs</i> .....	386
<i>Histrelin implant</i> .....	386
Immunomodulatory drugs.....	386
MAbs for prostate cancer .....	386
PACLIMER Microspheres.....	387
PRX302 .....	387
Targeted therapies for prostate cancer .....	388
<i>Delivery of cisplatin to prostate cancer by nanoparticles</i> .....	388
<i>Delivery of siRNAs to prostate cancer with aptamer-siRNA chimeras</i> .....	388
<i>Delivery of siRNA for prostate cancer with metastases</i> .....	388
<i>Gold nanoparticles targeted to laminin receptor in prostate cancer</i> .....	388
<i>PSA-activated protoxin that kills prostate cancer</i> .....	389
<i>Targeted delivery of a nanoparticulate platinum prodrug</i> .....	389
<i>Targeting oncogene MDM2 in prostate cancer</i> .....	389
<i>Vascular targeting of prostate cancer</i> .....	390
Gene therapy for cancer of prostate .....	390
<i>Experimental studies</i> .....	390
<i>Nanoparticle-based gene therapy for prostate cancer</i> .....	390
<i>Tumor suppressor gene therapy in prostate cancer</i> .....	391
<i>Vaccines for prostate cancer</i> .....	391

<i>Clinical trials of gene therapy for prostate cancer</i> .....	392
Viral oncolysis for prostate cancer .....	393
Combined approaches .....	393
Combined autovaccination and hyperthermia .....	393
<b>Thyroid cancer</b> .....	<b>394</b>
<b>6. Cancer drug delivery markets</b> .....	<b>395</b>
<b>Introduction</b> .....	<b>395</b>
Global markets for drug delivery .....	395
Estimation of cancer drug delivery markets .....	395
<i>Methods used for market estimation</i> .....	395
<i>Cancer epidemiology</i> .....	396
<i>Cost of patient care in cancer</i> .....	397
<b>Market forecasts 2017-2027</b> .....	<b>398</b>
Cancer drug market .....	398
<i>Market for leukemia</i> .....	399
<i>Market for lymphoma</i> .....	399
<i>Markets for brain tumors</i> .....	400
<i>Market for breast cancer</i> .....	400
<i>Market for ovarian cancer</i> .....	400
<b>Geographical distribution of cancer markets</b> .....	<b>400</b>
Factors affecting future cancer markets .....	400
<b>Market share according to cancer drug delivery technologies</b> .....	<b>401</b>
Antiangiogenesis therapies .....	402
Antibody drug conjugates .....	402
Antineoplastic drug implants for systemic administration .....	402
Antisense therapy and RNAi .....	402
Cancer vaccines .....	403
Cell/gene therapy .....	403
Liposomes for anticancer drugs .....	403
Monoclonal antibodies .....	404
Modulators of protein ubiquitination .....	404
<b>Strategic aspects of cancer drug delivery</b> .....	<b>404</b>
<b>Unmet needs in cancer drug delivery</b> .....	<b>405</b>
<b>Future of cancer drug delivery</b> .....	<b>405</b>
Cancer drug delivery and pharmacogenomics .....	406
Cancer immunotherapy markets .....	406
Drug delivery for cancer in the postgenomic era .....	406
Role of nanobiotechnology in development of cancer drug delivery markets .....	406
Expansion of cancer drug delivery markets in developing countries .....	406
Drivers for the development of drug delivery technologies in cancer .....	407
<b>7. References</b> .....	<b>409</b>

## Tables

Table 1-1: Estimated new cases of cancer in the US at most involved organs – 2016 .....	47
Table 1-2: Historical landmarks in drug delivery for cancer .....	51
Table 2-1: Innovative strategies against cancer .....	53
Table 2-2: A classification of antiangiogenic therapies .....	56
Table 2-3: Selected antiangiogenic agents in development for cancer .....	62
Table 2-4: Approaches to cancer therapy based on bacteria .....	64
Table 2-5: Cell therapy technologies used for cancer .....	72
Table 2-6: Non-nucleic acid cancer vaccines without genetic modification .....	77
Table 2-7: Monoclonal antibodies for cancer approved by the FDA .....	89
Table 2-8: Anticancer agents linked to monoclonal antibodies .....	94
Table 2-9: Monoclonal antibodies in clinical trials for cancer .....	97
Table 2-10: Antibody drug conjugates in clinical trials for cancer .....	104
Table 2-11: Third generation boron delivery agents currently under investigation .....	108
Table 2-12: Cellular pathways as targets for anticancer therapies .....	116
Table 2-13: Examples of anticancer agents that target mitochondrial membranes .....	118
Table 2-14: Drugs targeting oncogenes .....	122
Table 2-15: PARP inhibitors for cancer therapy .....	144
Table 2-16: Cancer therapies based on the P53 .....	149
Table 2-17: Promise of personalized therapy in cancer .....	154
Table 2-18: Companies developing personalized therapy for cancer .....	154
Table 3-1: Routes of drug delivery in cancer .....	160
Table 3-2: Systemic intravenous drug delivery systems for chemotherapy of cancer .....	160
Table 3-3: Approved oral chemotherapy drugs .....	162

Table 3-4: Microparticles as therapeutic delivery systems in cancer .....	175
Table 3-5: Classification of nanobiotechnology approaches to drug delivery in cancer.....	180
Table 3-6: Approved anticancer drugs using nanocarriers .....	181
Table 3-7: Clinical trials of anticancer drugs using nanocarriers .....	181
Table 3-8: Marketed preparations for liposome-based anticancer drugs .....	225
Table 3-9: Clinical trials of liposome-based anticancer drugs .....	226
Table 3-10: Strategies for drug delivery in cancer.....	230
Table 3-11: Implant systems for delivery of anticancer drugs into tumors.....	232
Table 3-12: Methods of delivery of antiangiogenesis therapies.....	252
Table 3-13: Companies developing vascular targeting agents.....	254
Table 4-1: Mechanisms of anticancer effect of antisense oligonucleotides .....	266
Table 4-2: Methods of delivery of oligonucleotides for cancer therapy .....	268
Table 4-3: Antisense oligonucleotides in clinical trials for cancer .....	274
Table 4-4: Companies developing antisense and RNAi therapies for cancer .....	280
Table 4-5: Strategies for cancer gene therapy .....	282
Table 4-6: Enzyme/prodrug combinations employed in suicide gene therapy.....	295
Table 4-7: Mutation compensation strategies used clinically .....	296
Table 4-8: Companies developing oncolytic viruses .....	309
Table 4-9: Companies involved in cancer gene therapy .....	312
Table 4-10: Cell therapy technologies used for cancer .....	314
Table 4-11: Companies developing nucleic acids/genetically modified cells-based cancer vaccines .....	322
Table 5-1: Innovative methods of drug delivery for glioblastoma multiforme.....	328
Table 5-2: Strategies for gene therapy of malignant brain tumors.....	345
Table 5-3: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	353
Table 5-4: Therapies for breast cancer involving innovative methods of drug delivery .....	355
Table 5-5: Drug delivery for hepatocellular carcinoma .....	362
Table 5-6: Gene therapy for malignant melanoma .....	370
Table 5-7: Targeted treatment of non-small cell lung cancer .....	373
Table 5-8: Clinical trials of gene therapy in ovarian cancer.....	376
Table 5-9: Methods of drug delivery in pancreatic cancer.....	380
Table 5-10: Pharmacological strategies under investigation for cancer of the prostate.....	383
Table 5-11: Clinical trials of gene therapy for prostate cancer .....	392
Table 6-1: Worldwide drug delivery market growth 2017 to 2027 .....	395
Table 6-2: Worldwide prevalence of cancer according to type of cancer 2017-2027.....	396
Table 6-3: Estimated number of cancer patients in major markets 2017-2027 .....	397
Table 6-4: Worldwide anticancer drug sales for selected cancers from 2017 to 2027 .....	399
Table 6-5: Geographical distribution of cancer markets 2017-2027 .....	400
Table 6-6: Market values of cancer drug delivery technologies from 2017-2027.....	401

## Figures

Figure 1-1: Structure of PD-1 pathway .....	23
Figure 1-2: Nitric oxide: tumor enhancement or inhibition .....	34
Figure 1-3: Role of nitric oxide in angiogenesis.....	37
Figure 1-4: An overview of some key steps in tumor angiogenesis. ....	43
Figure 2-1: Targeting tumors with light-emitting engineered bacteria.....	66
Figure 2-2: Enhancing tumor-cell visibility to the immune system by viral mimicry .....	76
Figure 2-3: Schematic role of T helper cells in immune response to cancer .....	81
Figure 2-4: G-MAB™ technology.....	102
Figure 2-5: Antimetabolic anticancer effect of SR9243 by inhibiting Warburg effect.....	148
Figure 3-1: Cyclacel's Penetratin Transport System for delivery of drugs to targets.....	172
Figure 3-2: Micelle for drug delivery in cancer .....	186
Figure 3-3: Mechanism of action of Targaceutical drugs.....	239
Figure 3-4: VIADUR leuprolide acetate using DUROS implant technology .....	251
Figure 5-1: A concept of targeted drug delivery to GBM across the BBB.....	331
Figure 6-1: Unmet needs in cancer drug delivery .....	405